Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid Sequencing of Cabozantinib, Ipilimumab/Nivolumab, and Lenvatinib/Everolimus in ccRCC
NCT05188118Phase 1Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cabozantinib, ipilimumab, nivolumab, lenvatinib and everolimus in clear cell renal cell carcinoma (ccRCC), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Overall Response Rate at 6 months. Started Feb 2023; status: completed.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05188118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05188118.